Oligopin® contains French Maritime Pine Bark Extract

Placebo is a mixture of different inert compounds

Metabolic Syndrome

French Maritime Pine Bark Extract - 100mg/day

Oligopin®

Placebo

KGK Science Inc.

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Change in fasting blood sugar from baseline to day 84 between Oligopin® and placebo.

Change in fasting insulin between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting glucose between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting LDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting oxLDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting HDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting total cholesterol between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in postprandial glucose between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in BMI between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in waist circumference between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in systolic and diastolic blood pressure between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in heart rate between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in ALT between Oligopin® and placebo pre-baseline and day 84.

Change in AST between Oligopin® and placebo pre-baseline and day 84.

Change in total bilirubin between Oligopin® and placebo pre-baseline and day 84.

Change in creatinine between Oligopin® and placebo pre-baseline and day 84.

Change in sodium ion between Oligopin® and placebo pre-baseline and day 84.

Change in potassium ion between Oligopin® and placebo pre-baseline and day 84.

Change in chloride ion between Oligopin® and placebo pre-baseline and day 84.

Change in eGFR between Oligopin® and placebo pre-baseline and day 84.

Change in WBC count between Oligopin® and placebo pre-baseline and day 84.

Change in neutrophil count between Oligopin® and placebo pre-baseline and day 84.

Change in lymphocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in monocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in eosinophil count between Oligopin® and placebo pre-baseline and day 84.

Change in basophil count between Oligopin® and placebo pre-baseline and day 84.

Change in RBC count between Oligopin® and placebo pre-baseline and day 84.

Change in hemoglobin level between Oligopin® and placebo pre-baseline and day 84.

Change in hematocrit level between Oligopin® and placebo pre-baseline and day 84.

Change in platelet count between Oligopin® and placebo pre-baseline and day 84.

Change in MCV level between Oligopin® and placebo pre-baseline and day 84.

Change in MCH level between Oligopin® and placebo pre-baseline and day 84.

Change in MCHC level between Oligopin® and placebo pre-baseline and day 84.

Change in MPV level between Oligopin® and placebo pre-baseline and day 84.

Change in RDW level between Oligopin® and placebo pre-baseline and day 84.

Les Derives Resiniques et Terpeniques

6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test

3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test

Type 2 Diabetes Mellitus

Obesity

Given 30 min prior to oral glucose tolerance test

Hydrolyzed pine nut oil

Hydrolyzed pine nut oil and olive oil

Odense University Hospital

Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance

Effects of Pine Nut and Olive Oil as FFA1/FFA4 and GPR119 Agonists on Glucose Tolerance in Healthy Overweight or Obese Subjects

Appetite is measured by the use of Visual analog scales. Respondents specify their level of agreement to a statement on hunger, satiety, fullness, prospective food consumption and thirst by indicating a position along a continuous 100 mm line between two end-points (0 and 100 mm) which represent the extreme feelings related to the statement. In example: How hungry do you feel? 0mm represents: Not hungry at all and 100 mm represents: I have never been hungrier.

Gastrointestinal tolerability is measured by the use of Visual analog scales. Respondents specify their level of nausea, flatulence, abdominal pain, diarrhea and constipation by indicating a position along a continuous 100 mm line between two end-points (0 and 100 mm) which represent the extreme feelings related to the symptom in question. In example: Have you been constipated? 0mm represents: No,not at all and 100 mm represents: Yes, severely.

Karina Vejrum Sørensen

Cross-over study of 3 interventions; 1) no oil intake, 2)6g hydrolyzed pine nut oil and 3) combined intake of 3g hydrolyzed pine nut oil and 3g olive oil 30 minutes prior to an 6-hours oral glucose tolerance test (75g glucose).

A standard OGTT with no supplementation/intervention

Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil

Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil

Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.

Department of Endocrinology

Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.

Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance, Incretins, Appetite and Tolerability in Healthy Humans.

Area under the curve of Insulin and C-peptide

Visual analog scale - area under the curve

MSc, PhD-student

University of Southern Denmark

Subjects complete three oral glucose tolerance tests (OGTT) on different days, with a minimum of one week in between. First visit is a combined screening and baseline OGTT, with no supplementation. At the second and third visit subjects are randomly assigned to either 3 g of hydrolyzed pine nut oil or 6 g of hydrolyzed pine nut oil.

Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil

Type2 Diabetes Mellitus

Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT

Pine nut oil

FFAR Agonist on Incretins, Insulin, Lipids and Inflammation

Effects of a Naturally Occurring Dual FFAR Agonist on Incretins, Insulin Secretion, Lipids and Inflammation in Obesity and Type 2 Diabetes

Changes in blood after a 4hour OGTT (75 g glucose)

Subjects complete three oral glucose tolerance test (OGTT) on different days, with a minimum of one week in between. First visit is a combined screening and baseline OGTT, with no supplementation. The second and third visit subjects are randomly assigned to either 1 g of non-hydrolyzed pine nut oil or 1 g of hydrolyzed pine nut oil.

pinus/fetma

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance

Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.

FFAR Agonist on Incretins, Insulin, Lipids and Inflammation

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen